Magellan Bioanalytics translates information in blood serum into human health information. Blood contains thousands of peptides, lipids, and small molecules, as well as the detritus from all the cell processes in the body. As cells consume resources, produce outputs, die and are replaced, molecules of all types are distributed into the blood. These molecules provide a window in the health of the organism.
At Magellan we think of ourselves as molecular archaeologists: sifting through piles of discarded and broken artifacts to discover markers for processes that we cannot clearly see. By combining mass-spectrometry and machine learning, we discover indicators of a variety of conditions in the human body.
Magellan's technology has proven itself useful in identifying markers for a broad range of indications, which all can be detected from the same blood sample. Because computers are inexpensive and AI software, once created, is affordable to run, thousands of tests can be run against a single blood sample for the same cost as one.
Our goal is to develop a single serum-based assay that can predict, diagnose, stage, and recommend treatment for a variety of diseases simultaneously.
Marc Hansen (CEO, CSO), PhD, Stanford University, a Cancer Biology professor and entrepreneur. Marc formerly founded Frost Biologic (2008 - 2018), an oncology drug discovery company, and built the BIO-Innovation Ecosystem at BYU
Dan Olsen (CTO), PhD in Computer Science, University of Pennsylvania. Dan has 40 years of experience in developing AI and machine learning; IP consultant for tech companies in fortune 100; investment analyst and consultant for tech investment firms
Marc Oddou (Business Director). Marc previously founded Rincon Bio (2013 - Present), a cancer drug discovery CRO; former Biotech Market Analyst at Informa PLC; drug discovery bench researcher at Huntsman Cancer Institute. BS Biotechnology (BYU), MBA (University of Utah)